Virologic response after adoptive transfer of AdV-specific T cells for treatment of refractory AdV infection after allogeneic HSCT. ACT of hexon-specific T cells was performed in patients after allogeneic HSCT. The virologic response to ACT is shown in terms of viral copies in peripheral blood. Pre ACT refers to data analyzed before or at ACT. Patients are subdivided into 3 different groups according to the change of viral load after ACT: straight responders (n = 10) are defined as patients with a significant reduction of viremia (≥1 log) or clearance of the viral load after ACT, transient responders (n = 5) show a temporary decrease of viremia (≥1 log) or clearance of AdV with subsequent re-increase of the viral load thereafter, and nonresponders (n = 5) are patients with persistent or increasing levels of the viral load after ACT (detailed information on individual patients is provided in supplemental Data, supplemental Figure 2, and supplemental Table 2). qPCR results of <1000 copies per milliliter are represented as 1000 copies per milliliter in the figure. (A) The course of viremia after ACT for straight and transient responders. For transient responders, the minimum of AdV copies after ACT, the maximum of re-increasing AdV copies within the time period of 6 weeks after ACT, and the course of viremia in the time period >6 weeks after ACT are shown. Clearance of viremia after 6 weeks took place at a mean of 93 ± 37 days (range, 55 to 176 days). (B) Course of viremia in nonresponders. Time of death (days after ACT) of the different patients is indicated.